Table 4: Correlation between the age and the clinicopathological features associated with the stage and receptor-defined breast cancer subtypes among the British Patients.

VARIABLES BRITISH PATIENTS
AGE / Years (%)

(20-34) (35-49) (50-64) (= / > 65)
Total P Value
STAGE 9 (1.5)* 101 (16.6) 242 (39.9) 255 (42) 607 -
I 2 (22.2)** 45 (44.6) 153 (63.2) 169 (66.3) 369 < .00001
II 3 (33.3) 53 (52.5) 82 (33.9) 82 (32.2) 220
III 3 (33.3) 2 (1.9) 6 (2.5) 3 (1.2) 14
IV 1 (11.1) 1 (0.9) 1 (0.4) 1 (0.4) 4
TUMOR SIZE 17 (1.5) 203 (17.8) 431 (37.7) 493 (43.1) 1144 -
T1 5 (29.4) 110 (54.2) 291 (67.5) 317 (64.3) 723 0.00001
T2 7 (41.2) 84 (41.4) 125 (29) 153 (31) 369
T3 4 (23.5) 7 (3.4) 12 (2.8) 17 (3.4) 40
T4 1 (5.9) 2 (1.0) 3 (0.7) 6 (1.2) 12
 LYMPH NODE 15 (1.4) 198 (18.1) 417 (38.1) 465 (42.5) 1,095 -
N0 7 (46.7) 137 (69.2) 321 (77) 377 (81.1) 842 0.0008
N1 5 (33.3) 55 (27.8) 82 (19.7) 72 (15.5) 214
N2 2 (13.3) 4 (2.0) 9 (2.2) 10 (2.2) 25
N3 1 (6.7) 2 (1.0) 5 (1.2) 6 (1.3) 14
ER STATUS 15 (1.2) 215 (16.9) 487 (38.3) 555 (43.6) 1272 -
ER Positive 12 (80) 180 (83.7) 425 (87.3) 483 (87) 1100 0.5049
ER Negative 3 (20) 35 (16.3) 62 (12.7) 72 (13) 172
PR STATUS 7 (1.3) 100 (18.4) 197 (36.3) 239 (44) 543 -
PR Positive 6 (85.7) 82 (82) 159 (80.7) 186 (77.8) 433 0 .7701
PR Negative 1 (14.3) 18 (18) 38 (19.3) 53 (22.2) 110
HER2 STATUS 14 (1.2) 192 (16.9) 440 (38.7) 492 (43.2) 1138 -
HER2 Positive 5 (35.7) 44 (22.9) 56 (12.7) 38 (7.7) 143 < .00001
HER2 Negative 9 (64.3) 148 (77.1) 384 (87.3) 454 (92.3) 995
SUBTYPES 7 (1.8) 73 (18.8) 144 (37) 165 (42.4) 389 -
Luminal A 4 (57.1) 54 (74) 124 (86.1) 143 (86.7) 325 0.0681
Luminal B 1 (14.3) 11 (15.1) 11 (7.6) 8 (4.8) 31
HER2 Enriched 1 (14.3) 3 (4.1) 4 (2.8) 3 (1.8) 11
Triple Negative 1 (14.3) 5 (6.8) 5 (3.5) 11 (6.7) 22

*Percent of Total Raw
**Percent of Total Column